LLY

950.5

-2.13%↓

JNJ

221.23

+0.16%↑

ABBV

200.62

-0.79%↓

UNH

373.73

+1.81%↑

AZN

181.88

+0.21%↑

LLY

950.5

-2.13%↓

JNJ

221.23

+0.16%↑

ABBV

200.62

-0.79%↓

UNH

373.73

+1.81%↑

AZN

181.88

+0.21%↑

LLY

950.5

-2.13%↓

JNJ

221.23

+0.16%↑

ABBV

200.62

-0.79%↓

UNH

373.73

+1.81%↑

AZN

181.88

+0.21%↑

LLY

950.5

-2.13%↓

JNJ

221.23

+0.16%↑

ABBV

200.62

-0.79%↓

UNH

373.73

+1.81%↑

AZN

181.88

+0.21%↑

LLY

950.5

-2.13%↓

JNJ

221.23

+0.16%↑

ABBV

200.62

-0.79%↓

UNH

373.73

+1.81%↑

AZN

181.88

+0.21%↑

Home・Listă Acțiuni・Fate Therapeutics Inc

Fate Therapeutics Inc

Deschisă

SectorSănătate

2.37 1.72

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

2.16

Maxim

2.46

Indicatori cheie
By Trading Economics
Venit	-124K -32M
Vânzări	-372K 1.4M
EPS	-0.27
Marjă de profit	-2,364.792
Angajați	161
EBITDA	-13M -42M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+105.76% upside

Dividende
By Dow Jones
Următoarele câștiguri	11 mai 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	35M 209M
Deschiderea anterioară	0.65
Închiderea anterioară	2.37

Sentimentul știrilor

By Acuity

69%

31%

319 / 347 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

0.9101 / 1.14 Suport & Rezistență

Fate Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

7 mai 2026, 23:58 UTC

Câștiguri

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7 mai 2026, 22:57 UTC

Câștiguri

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7 mai 2026, 23:52 UTC

Câștiguri

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7 mai 2026, 23:45 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7 mai 2026, 23:39 UTC

Market Talk

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7 mai 2026, 23:28 UTC

Market Talk

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7 mai 2026, 23:11 UTC

Câștiguri

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7 mai 2026, 23:06 UTC

Câștiguri

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7 mai 2026, 23:05 UTC

Câștiguri

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7 mai 2026, 23:04 UTC

Câștiguri

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7 mai 2026, 23:03 UTC

Câștiguri

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7 mai 2026, 23:03 UTC

Câștiguri

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7 mai 2026, 23:02 UTC

Câștiguri

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7 mai 2026, 23:00 UTC

Market Talk

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7 mai 2026, 22:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 mai 2026, 22:45 UTC

Market Talk

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7 mai 2026, 22:42 UTC

Câștiguri

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7 mai 2026, 22:33 UTC

Câștiguri

Achiziții, Fuziuni, Preluări

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 mai 2026, 22:32 UTC

Câștiguri

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7 mai 2026, 22:31 UTC

Câștiguri

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7 mai 2026, 22:31 UTC

Câștiguri

Macquarie: 68% of FY Income From International >MQG.AU

7 mai 2026, 22:30 UTC

Câștiguri

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7 mai 2026, 22:30 UTC

Câștiguri

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7 mai 2026, 22:29 UTC

Câștiguri

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7 mai 2026, 22:28 UTC

Câștiguri

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7 mai 2026, 22:28 UTC

Câștiguri

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7 mai 2026, 22:27 UTC

Câștiguri

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7 mai 2026, 22:27 UTC

Câștiguri

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7 mai 2026, 22:26 UTC

Câștiguri

Macquarie to End Share Buyback Extended in November>MQG.AU

7 mai 2026, 22:25 UTC

Câștiguri

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Comparație

Modificare preț

Fate Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

105.76% sus

Prognoză pe 12 luni

Medie 5 USD 105.76%

Maxim 7 USD

Minim 2 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruFate Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

5 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 5 analiști care au acordat evaluări ale acțiunilor Fate Therapeutics Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

0.9101 / 1.14Suport & Rezistență

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

319 / 347 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.